Beyond Conventional CARs: Expanding the Targetable Antigen Landscape in CAR-T Cell Therapy.

Area of Science:

• Immunotherapy
• Cellular Therapy
• Cancer Treatment

Background:

• Chimeric antigen receptor (CAR)-T cell therapy is a cornerstone of immunotherapy, with successes in B cell malignancies and multiple myeloma.
• Current CAR-T limitations include targeting only extracellular antigens and potential off-tumor toxicities due to shared antigens.

Purpose of the Study:

• To provide a comprehensive overview of novel CAR architectures designed to overcome current limitations.
• To expand the range of targetable antigens and reduce off-tumor toxicities in CAR-T cell therapy.

Main Methods:

• Review of recent advancements in CAR design, focusing on innovative architectures.
• Categorization of novel CARs into four main types: peptide-MHC-targeting, ultra-precision, ligand/receptor-based, and non-protein antigen-targeting CARs.

Main Results:

• Innovative CAR designs enable targeting of intracellular proteins via peptide-MHC recognition.
• Ultra-precision CARs offer enhanced specificity for pathogenic cells, sparing healthy counterparts.
• Ligand/receptor-based and non-protein antigen-targeting CARs further broaden the scope of CAR-T applications.

Conclusions:

• Advances in CAR architecture are crucial for expanding CAR-T cell therapy beyond current applications.
• New CAR designs hold potential for treating a wider array of hematologic malignancies, solid tumors, and autoimmune diseases with improved safety profiles.